Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 199.20

+0.1%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Torben Noerup Nielsen who wrote (29954)	1/7/2000 10:04:00 PM
From: bob zagorin	Read Replies (6) of 32384

brand new issue of CTSL has long write up on LGND and the plethora of news recently. here's excerpt on the Targretin approval. "...The biggest news came December 30 th ,when the FDA approved once-daily oral Targretin (bexarotene)cap- sules for patients with both early and advanced stages of refractory cutaneous T-cell lymphoma (CTCL).This is particularly good news,considering that last month the FDA Oncology Drugs Advisory Committee (ODAC)voted in favor of approving Targretin capsules for only advanced CTCL.The quid pro quo of the FDA ?s approval for all stages of refractory CTCL is that LGND carry out post approval Phase IV clinical and pharmacokinetic studies to further understand the long-term effects of the drug..."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next